Exact Sciences Raises Net Proceeds of $57.8M in Public Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Exact Sciences has raised $57.8 million in net proceeds from its public offering, the Madison, Wis.-based firm announced after the close of the market on Monday.

The company sold a total of 6,325,000 shares of its common stock at $9.75 per share. Jefferies and Co. and R.W. Baird were joint book-running managers in the offering, and William Blair & Co. and JMP Securities were co-managers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.